Ethnicity & Disease, Vol. 18, Supplement 2: Research Centers in Minority Institutions (RCMI): Current Science (Spring 2008), pp. 1-8 (8 pages) Introduction: Mdm2 inhibits p53 transactivation by ...

Almost half of patients with advanced solid tumors or lymphomas experienced disease control with a drug that reactivates the TP53 tumor suppressor, a first-in-human study showed. Overall, the oral ...

Overexpression of c-met as a Prognostic Indicator for Transitional Cell Carcinoma of the Urinary Bladder: A Comparison With p53 Nuclear Accumulation PURPOSE: Testicular germ cell tumors (TGCTs) of ...

Phase II study to evaluate surufatinib in patients with osteosarcoma and soft tissue sarcoma that has failed standard chemotherapy: Updated analysis. This is an ASCO Meeting Abstract from the 2024 ...

The oncoprotein MDM2 (murine double minute 2) is often overexpressed in human tumors and thereby attenuates the function of the tumor suppressor p53. In this study, we investigated the effects of the ...

Researchers from Walter and Eliza Hall Institute of Medical Research, The University of Melbourne and affiliated organizations presented the development of a new reporter mouse model designed to study ...

Scientists at the Karolinska Institutet in Sweden published a paper (“Pharmacological activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor ...

The Myc family of transcription factors, including Myc, N-Myc, and L-Myc, bind DNA at specific sequences and regulate gene expression by binding to enhancer-box (E-Box) sequences via dimerization with ...

Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window CHICAGO -- ...